These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 22619999)
1. [Perspective of proteomic studies for discovering biomarkers of diabetes and obesity]. Kaburagi Y; Unoki-Kubota H Nihon Rinsho; 2012 May; 70(5):769-73. PubMed ID: 22619999 [TBL] [Abstract][Full Text] [Related]
2. [Alpha2-macroglobulin in diabetic disease and in its microangiopathic complications]. Volpi A; Piaserico PL Minerva Med; 1983 Oct; 74(39):2287-9. PubMed ID: 6197682 [TBL] [Abstract][Full Text] [Related]
3. Recent technological developments in proteomics shed new light on translational research on diabetic microangiopathy. Ma Y; Yang C; Tao Y; Zhou H; Wang Y FEBS J; 2013 Nov; 280(22):5668-81. PubMed ID: 23763694 [TBL] [Abstract][Full Text] [Related]
4. [Diabetes mellitus: the role of metabolic control in the prevention of complications]. Gomez F; Chabot V Schweiz Med Wochenschr; 1983 Sep; 113(38):1342-5. PubMed ID: 6415812 [TBL] [Abstract][Full Text] [Related]
5. [Diabetes mellitus: Management of metabolism and microangiopathy]. Mehnert H Ther Ggw; 1974 Sep; 113(9):1464-74. PubMed ID: 4439322 [No Abstract] [Full Text] [Related]
6. Rheological changes in diabetic microangiopathy. Negrean V; Suciu I; Sâmpelean D; Cozma A Rom J Intern Med; 2004; 42(2):407-13. PubMed ID: 15529630 [TBL] [Abstract][Full Text] [Related]
7. The problems of tissue oxygenation in diabetes mellitus. III. The "three-in-one concept" for the development of diabetic microangiopathy and a rational approach to its prophylaxis. Ditzel J Acta Med Scand Suppl; 1975; 578():69-83. PubMed ID: 1057374 [TBL] [Abstract][Full Text] [Related]
8. Diabetes mellitus a risk for osteoporosis? Leidig-Bruckner G; Ziegler R Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S493-514. PubMed ID: 11460594 [TBL] [Abstract][Full Text] [Related]
9. Sialic Acid, possible marker of angiopathic complications at diabetics type 2. Faur L; Motocu M; Moldovan C; Onaca M; Muţiu G Rom J Morphol Embryol; 2005; 46(4):307-9. PubMed ID: 16688368 [TBL] [Abstract][Full Text] [Related]
10. Proteomic identification of salivary biomarkers of type-2 diabetes. Rao PV; Reddy AP; Lu X; Dasari S; Krishnaprasad A; Biggs E; Roberts CT; Nagalla SR J Proteome Res; 2009 Jan; 8(1):239-45. PubMed ID: 19118452 [TBL] [Abstract][Full Text] [Related]
11. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners]. Fabian W; Majkowska L; Stefański A; Moleda P Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234 [TBL] [Abstract][Full Text] [Related]
12. [Diabetic microangiopathy]. García-Conde Gómez FJ An R Acad Nac Med (Madr); 1986; 103(2):173-89. PubMed ID: 3799953 [No Abstract] [Full Text] [Related]
13. Neutrophil surface expression of CD11b and CD62L in diabetic microangiopathy. Mastej K; Adamiec R Acta Diabetol; 2008 Sep; 45(3):183-90. PubMed ID: 18496641 [TBL] [Abstract][Full Text] [Related]
14. Growth hormone's role in diabetic microangiopathy. Lundbaek K Diabetes; 1976; 25(2 SUPPL):845-9. PubMed ID: 985606 [TBL] [Abstract][Full Text] [Related]
19. Can adequate control of diabetes prevent the development of vascular complications? A mini review. Ostman J Acta Med Scand Suppl; 1983; 671():5-10. PubMed ID: 6349266 [TBL] [Abstract][Full Text] [Related]
20. [Frequency and seasonal biorhythm of metabolic indices and vascular lesions in diabetics]. Nikberg II; Efimov DA Vrach Delo; 1984 Nov; (11):57-60. PubMed ID: 6528561 [No Abstract] [Full Text] [Related] [Next] [New Search]